BioSpace News Archive

Alnylam Pharmaceuticals, Inc. announced today that management will present company overviews at the following conferences.

Devonian Health Group Inc. is pleased to announce that its wholly-owned subsidiary, Altius Healthcare Inc. has launched the first authorized generic of dexlansoprazole (Dexilant®) in Canada to treat symptoms of gastroesophageal reflux disease (GERD).

Mabwell (688062.SH) announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as “ESCC”).

Ginkgo Bioworks has announced the signing of an agreement with Qatar Free Zones Authority and Doha Venture Capital to build the first Center for Unified Biosecurity Excellence in Doha within Qatar Free Zones.

Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa, announced that they have successfully raised $1.7 million in bridge financing.

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.

Simmbion, The Living Medicine Company™, is excited to announce that Greg Merril has been appointed as Executive Director, joining the pioneering team led by Founding CEO

Cerevance today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Biom Pharmaceutical, a microbiome biotech company, announced the publication of the results of the clinical study on VagiBiom® microbiome-based probiotic suppositories, the company’s flagship feminine care product.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.